NASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis $140.02 +0.68 (+0.49%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$139.97 -0.05 (-0.04%) As of 03/21/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Repligen Stock (NASDAQ:RGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Repligen alerts:Sign Up Key Stats Today's Range$135.71▼$140.3950-Day Range$136.99▼$174.2452-Week Range$113.50▼$198.00Volume623,142 shsAverage Volume651,868 shsMarket Capitalization$7.86 billionP/E RatioN/ADividend YieldN/APrice Target$178.64Consensus RatingModerate Buy Company OverviewRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More… Remove Ads Repligen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreRGEN MarketRank™: Repligen scored higher than 95% of companies evaluated by MarketBeat, and ranked 43rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 8 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageRepligen has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Repligen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth37.21% Earnings GrowthEarnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is -274.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is -274.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioRepligen has a PEG Ratio of 4.54. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Repligen's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.52% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Repligen has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted6.52% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Repligen has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.90 News SentimentRepligen has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Repligen this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $37,672.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repligen's insider trading history. Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Stock News HeadlinesMargaret Pax Buys 250 Shares of Repligen Co. (NASDAQ:RGEN) StockMarch 19, 2025 | insidertrades.comInsider Buying: Margaret Pax Acquires Shares of Repligen Corp (RGEN)March 21 at 9:04 PM | gurufocus.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.March 23, 2025 | Brownstone Research (Ad)Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth and valuation challengesMarch 21 at 8:26 PM | uk.investing.comRepligen: Ongoing Bioprocessing Market RecoveryMarch 20 at 7:56 AM | seekingalpha.comRepligen (NASDAQ:RGEN) Earns In-Line Rating from Analysts at Evercore ISIMarch 20 at 2:49 AM | americanbankingnews.comRepligen Director Makes a Multi-Million Dollar Stock Move!March 19, 2025 | tipranks.com5RGEN : Demystifying Repligen: Insights From 6 Analyst ReviewsMarch 18, 2025 | benzinga.comSee More Headlines RGEN Stock Analysis - Frequently Asked Questions How have RGEN shares performed this year? Repligen's stock was trading at $143.94 at the beginning of 2025. Since then, RGEN shares have decreased by 2.7% and is now trading at $140.02. View the best growth stocks for 2025 here. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) released its quarterly earnings results on Thursday, February, 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The biotechnology company earned $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive trailing twelve-month return on equity of 4.21%. Does Repligen have any subsidiaries? Repligen subsidiaries include these companies: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others. Who are Repligen's major shareholders? Top institutional investors of Repligen include Price T Rowe Associates Inc. MD (12.74%), Vanguard Group Inc. (9.10%), Champlain Investment Partners LLC (2.75%) and Impax Asset Management Group plc (1.88%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings2/20/2025Today3/23/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees2,020Year Founded1981Price Target and Rating Average Stock Price Target$178.64 High Stock Price Target$205.00 Low Stock Price Target$155.00 Potential Upside/Downside+27.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E Ratio81.41 P/E Growth4.54Net Income$35.60 million Net Margins-4.64% Pretax Margin-4.26% Return on Equity4.21% Return on Assets2.94% Debt Debt-to-Equity Ratio0.26 Current Ratio10.44 Quick Ratio8.76 Sales & Book Value Annual Sales$634.44 million Price / Sales12.39 Cash Flow$2.61 per share Price / Cash Flow53.61 Book Value$35.19 per share Price / Book3.98Miscellaneous Outstanding Shares56,149,000Free Float55,355,000Market Cap$7.86 billion OptionableOptionable Beta0.95 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:RGEN) was last updated on 3/23/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.